XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.
- Author:
Peng YUAN
1
;
Xiao-ping MIAO
;
Xue-mei ZHANG
;
Zhong-hua WANG
;
Wen TAN
;
Yan SUN
;
Xiang-ru ZHANG
;
Bing-he XU
;
Dong-xin LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carboplatin; administration & dosage; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; Cisplatin; administration & dosage; DNA Repair; genetics; DNA-Binding Proteins; genetics; Female; Genotype; Humans; Lung Neoplasms; drug therapy; genetics; Male; Middle Aged; Paclitaxel; administration & dosage; Polymorphism, Genetic; Remission Induction; Vinblastine; administration & dosage; analogs & derivatives; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein; genetics
- From: Chinese Journal of Oncology 2006;28(3):196-199
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEDNA repair system plays an important role in tumor sensitivity to platinum-based chemotherapy. The purpose of this study was to examine the association between polymorphisms in XRCC1 and XPD, which are involved in DNA repair, and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
METHODSXRCC1 Arg194Trp and XPD Lys751Gln were genotyped by PCR-RFLP method in 200 patients with advanced NSCLC who received platinum-based chemotherapy. Unconditional logistic regression model was used to analyze the association between genetic polymorphisms and clinical responses.
RESULTSThe overall response rate (CR + PR) was 36.0%, including 1 CR, 72 PR, 94 SD and 34 PD. The XRCC1 194Trp allele carriers had higher response rate than the subjects with the Arg/Arg genotype (adjusted OR, 2.48; 95% CI, 1.36 - 4.51, P = 0.003). However, the XPD Lys751Gln polymorphism was not found to be associated with the platinum-based chemotherapy. These two genetic polymorphisms may have some interaction in the drug sensitivity, the P value for the trend was significant (P = 0.004).
CONCLUSIONThose results suggest that the XRCC1 Arg194Trp and XPD Lys751Gln genetic polymorphisms may be associated with clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.
